Itraconazole is a powerful anti-cancer repurposed drug — as strong as ivermectin and fenbendazole in many respects.

But unlike those two, it already has completed Phase II human clinical trials in cancer.

That alone should put it on every oncologist’s radar. It has not. Here is why it should be, and what the evidence actually shows.

What Is Itraconazole?

Itraconazole is a triazole antifungal approved by the FDA over 30 years ago. It has been used safely in millions of patients for infections ranging from athlete’s foot to invasive systemic fungal disease.

It is cheap, widely available, and has a long, well-characterized safety profile.

But the same properties that make it effective against fungi — its ability to inhibit critical signaling pathways — turn out to make it a serious anti-cancer agent when used at the right doses.

How Itraconazole Fights Cancer

Itraconazole hits cancer through five separate mechanisms, several of which no other single drug in the metabolic toolbox covers this well.

1. Hedgehog pathway blockade

The Hedgehog pathway is one of the three master pathways that keep cancer stem cells alive (alongside Wnt/β-catenin and Notch). It is overactive in basal cell carcinoma, medulloblastoma, and many pancreatic, ovarian, and lung cancers.

Itraconazole is one of the few natural or repurposed compounds that directly inhibits Hedgehog signaling — and does it powerfully.

2. Anti-angiogenesis

Itraconazole blocks VEGFR2 and the mTOR-driven pathways that build new tumor blood vessels. Cutting off angiogenesis starves the tumor of oxygen and nutrients.

This is the same mechanism targeted by expensive drugs like bevacizumab (Avastin) — except itraconazole costs pennies per dose.

3. mTOR suppression

Itraconazole suppresses the mTOR pathway — the master growth switch of cancer. This puts it in the same functional category as metformin, berberine, and rapamycin, but through a different upstream mechanism.

4. Wnt/β-catenin suppression

Along with ivermectin and fenbendazole, itraconazole targets Wnt/β-catenin — the primary cancer stem cell survival pathway. This is critical for preventing recurrence.

5. P-glycoprotein inhibition — reversing chemotherapy resistance

This is the underappreciated mechanism.

P-glycoprotein is a pump on the surface of cancer cells that ejects chemotherapy drugs before they can work. It is a major driver of chemotherapy resistance.

Itraconazole inhibits P-glycoprotein — meaning it can restore sensitivity to chemotherapy drugs that have stopped working. For patients on chemo who are watching their treatment lose effectiveness, this alone can be transformative.

📄 Repurposing itraconazole as an anticancer agent. Biochemical Pharmacology, 2017. 🔗 https://pubmed.ncbi.nlm.nih.gov/28789339/

The Human Clinical Evidence

This is where itraconazole stands apart from most other repurposed drugs. It is not just preclinical theory. It is documented in real human trials.

Prostate Cancer — Johns Hopkins Phase II

Johns Hopkins ran a Phase II trial in 46 men with metastatic castration-resistant prostate cancer — one of the most treatment-resistant forms of the disease.

Results with high-dose itraconazole:

• 48% were progression-free at 24 weeks
• Median progression-free survival of 36 weeks
• 12 of 14 patients showed reduced circulating tumor cells

For metastatic castration-resistant prostate cancer, these are meaningful numbers — achieved with an antifungal drug repurposed off-label.

📄 Antonarakis ES et al. Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer. The Oncologist, 2013. 🔗 https://pubmed.ncbi.nlm.nih.gov/23340005/

Basal Cell Carcinoma — Phase II

A Phase II trial in basal cell carcinoma patients confirmed itraconazole’s Hedgehog pathway inhibition in humans, with measurable reductions in tumor proliferation markers.

This is significant because it proved the mechanism translates from cell culture to actual human tumors — a critical step most repurposed drugs never achieve.

📄 Kim DJ et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. Journal of Clinical Oncology, 2014. 🔗 https://pubmed.ncbi.nlm.nih.gov/24493717/

Lung, Ovarian, and Triple-Negative Breast Cancer

A review of multiple clinical studies found that adding itraconazole to standard treatment protocols improved both progression-free and overall survival in patients with:

• Non-small cell lung cancer
• Ovarian cancer
• Triple-negative breast cancer

📄 Repurposing drugs in oncology: itraconazole. eCancer Medical Science, 2015. 🔗 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406527/

Multiple cancers. Multiple institutions. Multiple positive results. Yet the drug remains off the radar of nearly every oncologist in practice.

Why This Matters

Itraconazole occupies a unique position in the repurposed drug landscape:

• FDA-approved — no regulatory grey area
• Over 30 years of safety data
• Widely available — any physician can prescribe it
• Affordable — generic and cheap
• Multi-target — hits five separate cancer pathways simultaneously
• Human trial data — Phase II evidence in multiple cancers
• Complementary to conventional treatment — actually reverses chemotherapy resistance through P-glycoprotein inhibition

Compare that to the newest FDA-approved cancer drugs — most of which cost hundreds of thousands of dollars, target a single pathway, work only in patients with specific mutations, and carry severe toxicity profiles.

Itraconazole should be a first-line adjunct in nearly every solid tumor. It is not. The reason is not scientific — it is economic. An off-patent generic drug has no marketing budget behind it, no pharmaceutical company promoting it to oncologists, no continuing education courses funded to teach doctors how to use it.

That silence is the problem. The evidence is not.

Where Itraconazole Fits in a TMT Protocol

Within a Targeted Metabolic Therapy framework, itraconazole is a core component — especially valuable in cancers driven by:

• Cancer stem cell pathways — via Hedgehog and Wnt blockade
• Angiogenesis — highly vascular tumors including RCC, HCC, glioblastoma
• Chemotherapy resistance — where P-glycoprotein is limiting drug efficacy
• Advanced or metastatic prostate cancer
• Basal cell carcinoma — often as monotherapy
• Certain lung, ovarian, and triple-negative breast cancers

It pairs well with ivermectin (both hit Wnt, from different angles), fenbendazole (both hit mTOR and angiogenesis, through different mechanisms), and metformin (both suppress mTOR — reinforcing pressure).

Like all repurposed drugs in the TMT protocol, itraconazole must be used with proper dosing, monitoring, and liver support — because it is metabolized through CYP3A4 and can interact strongly with other drugs.

The Bottom Line

Itraconazole blocks Hedgehog, angiogenesis, mTOR, Wnt/β-catenin, and drug resistance — simultaneously.

• Phase II data already published in human cancer patients
• FDA-approved, affordable, widely available
• 30 years of safety data
• Complementary to conventional treatment — actually restores chemotherapy sensitivity

And most oncologists have never considered it.

This is why itraconazole is a core component of the Targeted Metabolic Therapy protocol. Not because of theory. Because of published human evidence — and because the biology it targets is exactly what cancer depends on to survive.

If your oncologist has not brought itraconazole into the conversation, bring it into the conversation yourself. The evidence has been there since 2013. It is time it was used.